Aquestive Therapeutics, Inc. AQST Manufacture and supply revenue — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported manufacture and supply revenue — revenue of $8.79M in Q1 2026.
- How has Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue increased by 22.2% year-over-year, from $7.19M to $8.79M.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s manufacture and supply revenue — revenue has grown at a 3.3% compound annual growth rate (CAGR), from $35.31M to $40.23M.
- What does manufacture and supply revenue — revenue mean?
- This metric represents the total gross revenue recognized from the manufacturing and supply of pharmaceutical products to third-party partners or customers. It reflects the company's ability to monetize its proprietary drug delivery platforms and manufacturing capabilities through contract manufacturing services. This revenue stream is a key indicator of the company's operational scale and its success in leveraging production infrastructure to support commercialized products.